Literature DB >> 26104246

Trophoblast calcyclin is elevated in placental tissue from patients with early pre-eclampsia.

P B B Schol1, C Güzel2, E A P Steegers3, R R de Krijger4, T M Luider5.   

Abstract

The aetiology of pre-eclampsia is thought to originate from aberrant spiral artery remodelling and invasion evoking cellular oxidative stress. Previously, we discovered differentially expressed proteins in trophoblast cells of pre-eclamptic pregnancies. One of these proteins is calcyclin (S100A6); a Ca(2+)-binding protein associated with cellular stress response. By immunohistochemistry on formalin-fixed paraffin-embedded placental tissue, calcyclin expression was compared between women with early pre-eclampsia (n=72) and non-hypertensive control patients (n=66) (χ(2), p=0.006) blindly by two observers. Significantly more intense staining was seen in trophoblast cells of pre-eclamptic pregnancies compared to control placentas suggesting that trophoblast calcyclin is elevated in early pregnancy.
Copyright © 2013 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Calcyclin; Pre-eclampsia; S100A6; Trophoblast

Year:  2013        PMID: 26104246     DOI: 10.1016/j.preghy.2013.11.003

Source DB:  PubMed          Journal:  Pregnancy Hypertens        ISSN: 2210-7789            Impact factor:   2.899


  2 in total

1.  Quantification of Calcyclin and Heat Shock Protein 90 in Sera from Women with and without Preeclampsia by Mass Spectrometry.

Authors:  Coşkun Güzel; Caroline B van den Berg; Johannes J Duvekot; Christoph Stingl; Thierry P P van den Bosch; Marcel van der Weiden; Eric A P Steegers; Regine P M Steegers-Theunissen; Theo M Luider
Journal:  Proteomics Clin Appl       Date:  2018-11-26       Impact factor: 3.494

Review 2.  Elucidating the Pathogenesis of Pre-eclampsia Using In Vitro Models of Spiral Uterine Artery Remodelling.

Authors:  Ross McNally; Abdelrahim Alqudah; Danilo Obradovic; Lana McClements
Journal:  Curr Hypertens Rep       Date:  2017-10-23       Impact factor: 5.369

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.